February 6, 2026
Lir Life Sciences Corp.
ISIN: CA50206C1005
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Vancouver, Canada – February 5, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company) is pleased to announce that it...
Read more >>LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Vancouver, Canada – January 29, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this...
Read more >LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
Vancouver, Canada – January 22, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance...
Read more >LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
Vancouver, Canada – January 15, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based...
Read more >LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
Vancouver, Canada – January 8, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a services agreement (“R&D Agreement”) with Neuland Laboratories Limited ("Neuland Labs"), a global contract development and manufacturing...
Read more >LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Vancouver, Canada – December 18, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global health expert and former Special Advisor to the Director General of the World Health Organization (WHO), has joined...
Read more >LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[i]-based therapies used in obesity and metabolic disease. LIR filed the...
Read more >Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 10, 2025 – Lir Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the “Study”) of GLP/GIP[i]-based obesity therapies, further advancing its novel transdermal platform for obesity...
Read more >